Rheumatoid Arthritis
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.
Study of LATE-onset RA (>65y), shows DMARD initiation is low in LORA; despite current clinical practice guidelines recommending early aggressive Rx. Among 3,373 LORA pts (age77 yrs), only 29% initiated on a DMARD. https://bit.ly/47dT6x6
Dr. John Cush RheumNow
1 year 11 months ago
256 Early RA pt cohort followed 10yrs showed SDAI sustained remission(n 48) had less 10 yr Xray progression (mTSS 4.06), vs sustained LDA (14.6) or MDA/HDA (21.04). Sustained remission pts were younger, lower HAQ & mTSS scores; less need for GC & bDMARDs https://t.co/92L7RTCx82 https://t.co/4uZBydcfRM
Dr. John Cush RheumNow
1 year 11 months ago
Analysis of the NOR-DMARD registry and Vienna #RA cohorts provided novel definitions for an RA flare, requiring an increase of
-4.7 on the SDAI or
-4.5 on the CDAI
Flare definitions correlated with functional and Xray outcomes. https://t.co/f2G2nYyyWT https://t.co/JczDZa9oUf
Dr. John Cush RheumNow
1 year 11 months ago
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today!
https://t.co/7OsdPYWukv https://t.co/QoCxR04bJD
Dr. John Cush RheumNow
1 year 11 months ago
Hong Kong study of 12233 RA pts followed 8.7 yrs, and 7% developed MACE. Daily Pred ≥5 mg signif increased the MACE risk (HR ~ 2), dose-dependent fashion; YET Pred <5 mg/d was not associated with MACE risk (vs No GC) https://t.co/26peaYp4kQ https://t.co/ooax9iTZYo
Dr. John Cush RheumNow
1 year 11 months ago
Innovative, full-read, state-of-the-art article on IMAGING in INFLAMMATORY ARTHRITIS & its future role in precision medicine. "Imaging is poised to become an invaluable tool in precision medicine..". HR-pQCT, 3T or 7T MRI, FAPI PET–CT, CEUS, FOI, etc https://t.co/fGQVEOkea9 https://t.co/XyvtZj85Hk
Dr. John Cush RheumNow
1 year 11 months ago
IL-2 receptor (sCD25) levels as a biomarker of RA-ILD? Study of 294 RA pts (56 w/ ILD) & 58 healthy controls (HCs) (ILD confirmed by HRCT). sCD25 sensitivity 51% & specificity 77%,; it elevated in RA-ILD subtypes (UIP, NSIP); but didnt correlate w/ HRCT https://t.co/1gJ635tu8a https://t.co/aYamfJwJi2
Poster Hall